Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582434 · ClinicalTrials.gov registry record · Early Phase 1
Experience With Topical Acne Treatment
A Early Phase 1 study of Acne, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05582434 is a Early Phase 1 study of Acne that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 72 participants, below the 140-participant average among 26 other Acne trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05582434, a Early Phase 1 study of Acne, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2
Conditions Studied
Interventions
- DRUG clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel
- DRUG adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel
- DRUG Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2026-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05582434
The ClinicalTrials.gov registry entry for NCT05582434 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 26 other Acne trials with a reported enrollment target (49% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 3 interventions - of which clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel is the first listed.
NCT05582434 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05582434 about?
NCT05582434 is a clinical study titled "Experience With Topical Acne Treatment". Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects...
What is the current status of trial NCT05582434?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2024-02-15. Estimated completion is 2026-11.
What conditions does trial NCT05582434 study?
This clinical trial studies the following conditions: Acne.
What interventions are being tested in trial NCT05582434?
The interventions under investigation include: clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel (DRUG), adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel (DRUG), Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel (DRUG).
Who is sponsoring clinical trial NCT05582434?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05582434 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
RECRUITING · Phase 1
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
RECRUITING · Phase 1
-
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
RECRUITING · Phase 1
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.